EP
TEVA icon

Eudaimonia Partners’s Teva Pharmaceuticals TEVA Stock Holding History

Eudaimonia Partners’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-1,007
Closed -$12K – 1261
2021
Q1 		$12K Buy
+1,007
New +$11.5K ﹤0.01% 1122

Other funds holding TEVA

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Berkshire Hathaway
Berkshire Hathaway Omaha, Nebraska $263B AUM 16.68% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACM
Abrams Capital Management Boston, Massachusetts $4.64B AUM 1.52% 1-Year Est. Return
MIFH
Migdal Insurance & Financial Holdings Petach Tikva, Israel $11.5B AUM 52.5% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
MMH
Menora Mivtachim Holdings Ramat Gan, Israel $21.1B AUM 40.03% 1-Year Est. Return
CI
Clal Insurance Tel-Aviv, Israel $16.6B AUM 68.34% 1-Year Est. Return
PF
Phoenix Financial Givatayim, Israel $10.5B AUM 49.21% 1-Year Est. Return

Eudaimonia Partners's TEVA Position: Q2 2021 in Review

Eudaimonia Partners sold out of Teva Pharmaceuticals (TEVA) in Q2 2021, closing a stake of 1,007 shares — an estimated $12K sold.

Eudaimonia Partners first reported a position in TEVA in Q1 2021 and held it in 1 quarter. The position peaked at $12K in Q1 2021. 440 funds tracked by Wall St. Rank hold TEVA as of Q2 2021.

  • Eudaimonia Partners reported no remaining Teva Pharmaceuticals position as of Q2 2021 after selling out during the quarter.
  • Eudaimonia Partners sold 1,007 Teva Pharmaceuticals shares in Q2 2021, an estimated $12K.
  • Eudaimonia Partners first reported a position in Teva Pharmaceuticals in Q1 2021 and held it in 1 quarter.
  • Eudaimonia Partners's Teva Pharmaceuticals position peaked at $12K in Q1 2021.
  • 440 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q2 2021.

Based on Eudaimonia Partners's 13F filing for Q2 2021, filed 13 Aug 2021.